reduces the plasma
levels of medroxyprogesterone
by at least half.
It has been suggested that to achieve adequate plasma medroxyprogesterone
acetate levels in breast cancer
therapy (above 100 nanograms/mL) a daily dose of 800 mg of Provera is probably necessary in the presence of aminoglutethimide
125 or 250 mg twice daily. This is double the usual recommended dose of this preparation.